Do Not Prescribe (DNP), Red
Decision Date:
September 2017



  • NICE TA466: for moderate to severe rheumatoid arthritis. Selective JAK1/JAK2 inhibitor, JAK3-sparing, treatment of moderate-to-severe active rheumatoid arthritis.  (Decision date - September 2017)
  • NICE TA681: for the treatment of moderate to severe atopic dermatitis.  (Decision date - April 2021)
  • For use in monogenic interferonopathies (adults and children 2 years and over). NHSE commissioned.  (Decision date - August 2021)

People admitted to hospital with COVID-19 who need high-flow oxygen: baricitinib can be offered, subject to eligibility criteria, through the UK interim clinical commissioning policies for secondary care. (Decision date - April 2023)


  •  NICE TA926: Baricitinib for treating severe alopecia areata. Baricitinib is not recommended, within its marketing authorisation, for treating severe alopecia areata in adults (Decision date - November 2023)

Do Not Prescribe (DNP) Drug Classifications

  • 1: Are classified by the BNF as 'less suitable for prescribing', and includes anti-malarials (where a private prescription may be provided). Have a lack of data on effectiveness compared with standard therapy
  • 2: Have a lack of data on safety compared with standard therapy
  • 4: Have a lack of data on cost-effectiveness compared with standard therapy
  • 5: Less cost-effective than current standard therapy

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app